Lupus Pill Missed Its Main Goal in a 408 Patient Trial and the Company Is Chasing a Subgroup

Alumis says envudeucitinib failed its primary endpoint in a 408-patient lupus trial but plans Phase 3 in a subgroup. Why that carries risk.

Have A Referral?